Immunesensor Therapeutics
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2110 Research Row Ste 610, Dallas, Texas...Phone Number
(469) 570-5330Website
www.immunesensor.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immunesensor Therapeutics
ImmuneSensor Therapeutics is a clinical-stage biotechnology company specializing in the development of innovative medicines that target the cGAS-STING pathway to modulate the innate immune system. The company aims to create best-in-class cGAS inhibitors to address inflammatory and autoimmune diseases, leveraging groundbreaking research from Dr. Zhijian James Chen. Their approach is based on the recognition of the cGAS-STING pathway's critical role in innate immunity and its potential in various therapeutic applications. ImmuneSensor Therapeutics is committed to advancing drug development efforts to improve patient outcomes in these challenging health areas.Explore more
Immunesensor Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunesensor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Immunesensor Therapeutics is spiking on competitors!
Earning: See what the market has to say on Immunesensor Therapeutics recently announced quarterly report
Product Launch: Get notified when Immunesensor Therapeutics launches new products
Immunesensor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immunesensor Therapeutics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Immunesensor Therapeutics has new funding data
Check if Immunesensor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Immunesensor Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Immunesensor Therapeutics
Find 3 more new buyers
Compare Similar Companies to Immunesensor Therapeutics
Compare insights from companies similar to Immunesensor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.5M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
Immunesensor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunesensor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunesensor Therapeutics.
Immunesensor Therapeutics financials insights
Gather financial insights about Immunesensor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Immunesensor Therapeutics Tech Stack
A closer look at the technologies used by Immunesensor Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Funding
Immunesensor Therapeutics has received an SBA PPP loan for $150,000 from Southwestern National Bank, supporting the retention of 11 jobs.
Funding
Immunesensor Therapeutics News & Media
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase 1b/2 clinical studies in patients with AGS, lupus and other cGAS-driven diseasesImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement of IMSB301 into Phase 1b/2 clinical studies in Type I interferonopathies Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement of IMSB301 into Phase 1b/2 clinical studies in Type I interferonopathiesImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of the cGAS pathwayImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium
DALLAS, Sept. 16, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting the cGAS-STING pathway to address diverse peripheral and CNS indications in inflammation, autoimmunity and oncology, announced that Tom Dubensky, Ph.D., ImmuneSensor’s president and chief executive officer, will present a corporate update at the UBS 2024 Virtual Biotechnology Private Company Symposi
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunesensor Therapeutics
Sign Up For FreeTo access detailed company insights
ImmuneSensor Therapeutics is a clinical-stage biotechnology company specializing in the development of innovative medicines that target the cGAS-STING pathway to modulate the innate immune system. The company aims to create best-in-class cGAS inhibitors to address inflammatory and autoimmune diseases, leveraging groundbreaking research from Dr. Zhi... Read More
